{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee I"],"funding":["NIH/NINDS","NINDS NIH HHS"],"pagination":["175-179"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11891797"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(1-2)"],"pubmed_abstract":["<h4>Objective</h4>A high glycemic index and high glycemic load diet has been associated with slower progression of amyotrophic lateral sclerosis (ALS), suggesting a benefit from high blood glucose levels. We examined the association between average blood glucose level and ALS progression in two independent cohorts.<h4>Methods</h4>Sporadic ALS patients enrolled in the ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS) who completed a 3-month follow-up visit and had available blood samples were included. Hemoglobin A1c (HbA1c) was measured from whole blood collected at the 3-month follow-up. From the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database, we included ALS patients with one or more HbA1c measurements at enrollment and available death information. Associations between HbA1c with revised ALS functional rating scale (ALSFRS-R)/ALSFRS total score change, and tracheostomy-free survival/survival were examined in these cohorts using linear regression, linear mixed-effects models, and Cox proportional hazard models, adjusted for covariates.<h4>Results</h4>In the ALS COSMOS cohort (<i>n</i> = 193), HbA1c level was not significantly associated with the change in the ALSFRS-R total score from baseline to the 3-month follow-up (<i>p</i> = 0.8) nor baseline to the 6-month follow-up (<i>p</i> = 0.4). No significant association was found between HbA1c level and tracheostomy-free survival (<i>p</i> = 0.8). In the PRO-ACT cohort (<i>n</i> = 928), no significant association was found between HbA1c level and the rate of ALSFRS decline in the first 200 days (<i>p</i> = 0.81 for interaction) nor between HbA1c level and survival (<i>p</i> = 0.45).<h4>Interpretation</h4>We did not find convincing evidence that mean blood glucose level is associated with disease progression among ALS patients."],"journal":["Amyotrophic lateral sclerosis & frontotemporal degeneration"],"pubmed_title":["Blood glycated hemoglobin level is not associated with disease progression in amyotrophic lateral sclerosis."],"pmcid":["PMC11891797"],"funding_grant_id":["K23 NS131586","K23NS131582"],"pubmed_authors":["Rosenbaum M","Vestrucci M","Lee S","Mitsumoto H","Lee I"],"additional_accession":[]},"is_claimable":false,"name":"Blood glycated hemoglobin level is not associated with disease progression in amyotrophic lateral sclerosis.","description":"<h4>Objective</h4>A high glycemic index and high glycemic load diet has been associated with slower progression of amyotrophic lateral sclerosis (ALS), suggesting a benefit from high blood glucose levels. We examined the association between average blood glucose level and ALS progression in two independent cohorts.<h4>Methods</h4>Sporadic ALS patients enrolled in the ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS) who completed a 3-month follow-up visit and had available blood samples were included. Hemoglobin A1c (HbA1c) was measured from whole blood collected at the 3-month follow-up. From the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database, we included ALS patients with one or more HbA1c measurements at enrollment and available death information. Associations between HbA1c with revised ALS functional rating scale (ALSFRS-R)/ALSFRS total score change, and tracheostomy-free survival/survival were examined in these cohorts using linear regression, linear mixed-effects models, and Cox proportional hazard models, adjusted for covariates.<h4>Results</h4>In the ALS COSMOS cohort (<i>n</i> = 193), HbA1c level was not significantly associated with the change in the ALSFRS-R total score from baseline to the 3-month follow-up (<i>p</i> = 0.8) nor baseline to the 6-month follow-up (<i>p</i> = 0.4). No significant association was found between HbA1c level and tracheostomy-free survival (<i>p</i> = 0.8). In the PRO-ACT cohort (<i>n</i> = 928), no significant association was found between HbA1c level and the rate of ALSFRS decline in the first 200 days (<i>p</i> = 0.81 for interaction) nor between HbA1c level and survival (<i>p</i> = 0.45).<h4>Interpretation</h4>We did not find convincing evidence that mean blood glucose level is associated with disease progression among ALS patients.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2026-06-17T04:52:43.49Z","creation":"2026-06-17T03:07:54.117Z"},"accession":"S-EPMC11891797","cross_references":{"pubmed":["39329381"],"doi":["10.1080/21678421.2024.2407409"]}}